Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acetaminophen + diphenhydramine + phenylephrine (Nik Saman Darou)
- Development stage
- Unknown
- Lead developer
- nik saman darou
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nixacold is an over-the-counter oral syrup formulation containing a combination of acetaminophen, diphenhydramine hydrochloride, and phenylephrine hydrochloride. Developed and manufactured by Nik Saman Darou, it is indicated for the temporary relief of symptoms associated with the common cold, influenza, and upper respiratory allergies, including fever, minor aches and pains, nasal congestion, and runny nose. Within this combination, acetaminophen acts as an analgesic and antipyretic by inhibiting prostaglandin synthesis, diphenhydramine hydrochloride serves as a first-generation antihistamine with sedative and anticholinergic properties, and phenylephrine hydrochloride functions as a selective alpha-1 adrenergic receptor agonist to relieve nasal congestion.
- Brand names
- Nixacold
- Other names
- acetaminophen + diphenhydramine hydrochloride + phenylephrine hydrochloride
02
Targets
ADRA1A (α1A)mAChR (Muscarinic acetylcholine receptors)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on acetaminophen + diphenhydramine + phenylephrine (Nik Saman Darou).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acetaminophen + diphenhydramine + phenylephrine (Nik Saman Darou).